Prof. Dr. rer. nat. Volker Schirrmacher
Wissenschaftlicher Leiter der Tumorimmunologie am IOZK
Wissenschaftlicher Leiter der Tumorimmunologie am IOZK
Prof. Dr. rer. nat. Volker Schirrmacher erhielt 1976 einen Ruf an das Deutsche Krebsforschungszentrum (DKFZ) in Heidelberg als Wissenschaftlicher Rat und Professor für Immunologie. 1979 habilitierte er sich in Immunologie in Heidelberg und 1986 wurde er ordentlicher Professor. Am DKFZ leitete er die Abteilung zelluläre Immunologie bis zu seiner Emeritierung 2008.
Seit 2008 ist er am IOZK Wissenschaftlicher Leiter der Tumorimmunologie. Sein Wissenschaftliches Œuvre umfasst fast 400 Veröffentlichungen in internationalen Fachzeitschriften.
1987 und 1988 war er Vorsitzender der Sektion Experimentelle Krebsforschung bei der Deutschen Krebsgesellschaft und 1989/80 Präsident der Metastasis Research Society. 2003 und 2004 vertrat er Deutschland bei der European Association of Cancer Research (EACR). Von 2009 bis 2011 war er Präsident der Europäischen Gesellschaft für Angewandte Immunologie e.V. (EGAI).
1982 erhielt er den Aronson-Preis und den Meyenburg-Preis und 1988 den Deutschen Krebspreis.
Er ist ein international anerkannter Pionier der Immuntherapie bei Krebs mit dem Schwerpunkt onkolytische Viren. Gemeinsam mit den Naturwissenschaftlern und Ärzten am IOZK arbeitet er an der systematischen Integration neuer wissenschaftlicher Erkenntnisse zur Weiterentwicklung der IOZK-Immuntherapie.
„Viren sind als Auslöser verschiedener Krankheiten bekannt. Weniger bekannt ist jedoch, dass bestimmte Viren für die Behandlung von Krebs eingesetzt werden. Vor über 100 Jahren beobachteten Ärzte erstmals, dass Patienten nach Virusinfektionen von ihrem Krebsleiden geheilt waren.“
Prof. Dr. rer. nat. Volker Schirrmacher
This post is also available in: Englisch Spanisch Russisch
Interview mit Prof. Dr. Volker Schirrmacher im Klassik Radio
/in IOZK Aktuelles, IOZK In der Presse /von arndslegersIndividualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution
/in International Publications, IOZK Aktuelles, IOZK Veröffentlichungen /von 2024-03-28 / Biomedicines 2024 Mar;12(4)Methods behind oncolytic virus-based DC vaccines in cancer: Toward a multiphase combined treatment strategy for Glioblastoma (GBM) patients
/in Dendritic Cells, Glioblastoma, Hyperthermia, International Publications, IOZK Aktuelles, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2023-10-19 / Methods Cell Biol 2024;183:51-113Dendritic cell vaccination for glioblastoma multiforme patients: has a new milestone been reached?
/in Dendritic Cells, Glioblastoma, International Publications, IOZK Aktuelles, IOZK Veröffentlichungen /von 2023-07-28 / Transl Cancer Res 2023 Aug;12(8):2224-2228The Application of Evidence-Based Medicine in Individualized Medicine
/in International Publications, IOZK Veröffentlichungen /von 2023-06-23 / Biomedicines 2023 Jun;11(7)Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience
/in Dendritic Cells, Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2023-02-13 / Cancers (Basel) 2023 Feb;15(4)Counteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy
/in International Publications, IOZK Veröffentlichungen /von 2022-10-27 / Int J Mol Sci 2022 Oct;23(21)Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients
/in Dendritic Cells, Glioblastoma, Hyperthermia, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2022-02-16 / Genes Immun 2022 Feb;Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged
/in Dendritic Cells, Glioblastoma, Hyperthermia, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2020-12-24 / Cancers (Basel) 2020 Dec;13(1)Mitochondria at Work: New Insights into Regulation and Dysregulation of Cellular Energy Supply and Metabolism
/in International Publications, IOZK Veröffentlichungen /von 2020-11-22 / Biomedicines 2020 Nov;8(11)Evidence-Based Medicine in Oncology: Commercial Versus Patient Benefit
/in International Publications, IOZK Veröffentlichungen /von 2020-07-23 / Biomedicines 2020 Jul;8(8)Position paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies
/in Dendritic Cells, Glioblastoma, Hyperthermia, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2020-06-30 / Expert Rev Anticancer Ther 2020 Aug;20(8):639-646IOZK Analyse belegt gute Verträglichkeit der IOZK Immuntherapie beim Diffusen intrinsischen pontinen Gliom (DIPG)
/in IOZK Veröffentlichungen /von IOZKAddition of Multimodal Immunotherapy to Combination Treatment Strategies for Children with DIPG: A Single Institution Experience
/in Brain Tumors in Children, Dendritic Cells, Hyperthermia, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2020-05-19 / Medicines (Basel) 2020 May;7(5)Prof. Dr. Volker Schirrmacher veröffentlicht zwei wegweisende Übersichtsartikel zur Immuntherapie
/in IOZK In der Presse, IOZK Veröffentlichungen /von IOZKCancer Vaccines and Oncolytic Viruses Exert Profoundly Lower Side Effects in Cancer Patients than Other Systemic Therapies: A Comparative Analysis
/in International Publications, IOZK Veröffentlichungen /von 2020-03-16 / Biomedicines 2020 Mar;8(3)New Insights into Mechanisms of Long-term Protective Anti-tumor Immunity Induced by Cancer Vaccines Modified by Virus Infection
/in Dendritic Cells, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2020-03-06 / Biomedicines 2020 Mar;8(3)Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2019-08-30 / Biomedicines 2019 Aug;7(3)Professor Volker Schirrmacher vom Kölner IOZK eröffnet die Tagung an der Universität zu Kiel mit seinem Vortrag zur Erforschung onkolytischer Viren im Zusammenhang der individuellen Krebs-Immuntherapie.
/in IOZK bei Fachtagungen /von IOZKFrom chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review)
/in International Publications, IOZK Veröffentlichungen /von 2018-12-10 / Int J Oncol 2019 Feb;54(2):407-419International Journal of Oncology: „Von der Chemotherapie zur biologischen Therapie“, Prof. Dr. Volker Schirrmacher
/in IOZK In der Presse, IOZK Veröffentlichungen /von IOZKIOZK-Artikel über Heilversuche bei Glioblastom im Fachorgan: „Austin Oncology Case Report“
/0 Kommentare/in IOZK Veröffentlichungen /von rootIOZK Vortrag: Modulierte Elektro-Hyperthermie bei Kindern mit DIPG, Konferenz der ESHO, Charité Berlin
/in IOZK bei Fachtagungen, IOZK Meldungen /von IOZKBuch Veröffentlichung von Prof. Dr. Schirrmacher: Quo vadis cancer therapy
/0 Kommentare/in IOZK Meldungen, IOZK Veröffentlichungen /von IOZKIOZK Artikel im International Journal of Molecular Sciences von Prof. Schirrmacher über die Rolle des Newcastle Disease Virus im Rahmen der Tumorimpfung,
/in IOZK In der Presse, IOZK Veröffentlichungen /von IOZKImmunobiology of Newcastle Disease Virus and Its Use for Prophylactic Vaccination in Poultry and as Adjuvant for Therapeutic Vaccination in Cancer Patients
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2017-05-20 / Int J Mol Sci 2017 May;18(5)IOZK Artikel von Prof. Schirrmacher in „Deutsche Zeitschrift für Onkologie“ über die Grundlagen der Immuntherapie
/in IOZK In der Presse, IOZK Veröffentlichungen /von IOZKIOZK Artikel im Austin Oncology Case Reports über Krebsimpfstoffe
/in IOZK In der Presse, IOZK Veröffentlichungen /von IOZKArtikel von Prof Schirrmacher in Biomedicines: „Fifty Years of Clinical Application of Newcastle Disease Virus“
/in IOZK Meldungen, IOZK Veröffentlichungen /von IOZKFachbeitrag von Prof. Schirrmacher zur Effizienz und Effektivität der Krebsbehandlung, Wiener klinisches Magazin
/in IOZK In der Presse, IOZK Veröffentlichungen /von IOZKExpertenbericht von Prof. Dr. Schirrmacher, Wiener klinisches Magazin
/in IOZK In der Presse, IOZK Veröffentlichungen /von IOZKBericht von Prof. Dr. Schirrmacher im International Journal of Oncology zu den Erkenntnissen der Tumor-reaktiven T-Zell-Memory im Knochenmark
/in IOZK Veröffentlichungen /von IOZKOncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2015-10-05 / Expert Opin Biol Ther 2015;15(12):1757-71IOZK Fallstudie zum Langzeitüberleben einer Patientin mit Brustkrebs
/in IOZK Meldungen, IOZK Veröffentlichungen /von IOZKBeitrag von Prof. Dr. Schirrmacher in der Wiener medizinischen Wochenschrift „Skriptum“
/in IOZK In der Presse, IOZK Veröffentlichungen /von IOZKLong-term survival of a breast cancer patient with extensive liver metastases upon immune and virotherapy: a case report
/in Breast Cancer, Dendritic Cells, Hyperthermia, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2015-05-28 / Immunotherapy 2015;7(8):855-60Prof. Dr. Schirrmacher veröffentlicht E-Book: Harnessing Oncolytic Virus-mediated Antitumor Immunity
/in IOZK Meldungen, IOZK Veröffentlichungen /von IOZKStrong T‑cell costimulation can reactivate tumor antigen‑specific T cells in late‑stage metastasized colorectal carcinoma patients: results from a phase Ⅰ clinical study
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2014-10-06 / Int. J. Oncol. 2015 Jan;46(1):71-7Long-term remission of prostate cancer with extensive bone metastases upon immuno- and virotherapy: A case report
/in Dendritic Cells, Hyperthermia, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus, Prostate Cancer /von 2014-10-06 / Oncol Lett 2014 Dec;8(6):2403-2406Multimodal cancer therapy involving oncolytic newcastle disease virus, autologous immune cells, and bi-specific antibodies
/in Dendritic Cells, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2014-09-11 / Front Oncol 2014;4:224Autologous tumor cell vaccines for post-operative active-specific immunotherapy of colorectal carcinoma: long-term patient survival and mechanism of function
/in Colorectal Cancer, Dendritic Cells, International Publications, IOZK Veröffentlichungen /von 2014-01-01 / Expert Rev Vaccines 2014 Jan;13(1):117-30Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host
/in Dendritic Cells, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2013-07-02 / Biology (Basel) 2013 Jul;2(3):936-75Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2013-02-01 / BioDrugs 2013 Feb;27(1):35-53Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2012-01-01 / Methods Mol. Biol. 2012;797:177-204Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2011-11-16 / Int. J. Oncol. 2012 Mar;40(3):840-50Importance of retinoic acid-inducible gene I and of receptor for type I interferon for cellular resistance to infection by Newcastle disease virus
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2011-10-04 / Int. J. Oncol. 2012 Jan;40(1):287-98Important role of interferon regulatory factor (IRF)-3 in the interferon response of mouse macrophages upon infection by Newcastle disease virus
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2011-05-09 / Int. J. Oncol. 2011 Aug;39(2):493-504Targeting of IL-2 and GM-CSF immunocytokines to a tumor vaccine leads to increased anti-tumor activity
/in Dendritic Cells, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2011-03-17 / Int. J. Oncol. 2011 Jun;38(6):1719-29Antitumor vaccination by Newcastle Disease Virus Hemagglutinin-Neuraminidase plasmid DNA application: changes in tumor microenvironment and activation of innate anti-tumor immunity
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2010-12-18 / Vaccine 2011 Feb;29(6):1185-93Transcriptome analysis and cytokine profiling of naive T cells stimulated by a tumor vaccine via CD3 and CD25
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2010-12-01 / Int. J. Oncol. 2010 Dec;37(6):1439-52Optimization studies for the coupling of bispecific antibodies to viral anchor molecules of a tumor vaccine
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2010-11-01 / Int. J. Oncol. 2010 Nov;37(5):1203-17The hemagglutinin-neuraminidase gene of Newcastle Disease Virus: a powerful molecular adjuvant for DNA anti-tumor vaccination
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2010-08-13 / Vaccine 2010 Oct;28(42):6891-900Polarization of human monocyte-derived dendritic cells to DC1 by in vitro stimulation with Newcastle Disease Virus
/in Dendritic Cells, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2009-09-01 / J BUON 2009 Sep;14 Suppl 1:S111-22Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2009-06-10 / J. Virol. 2009 Aug;83(16):8108-21Expression of RIG-I, IRF3, IFN-beta and IRF7 determines resistance or susceptibility of cells to infection by Newcastle Disease Virus
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2009-04-01 / Int. J. Oncol. 2009 Apr;34(4):971-82Cross-infection of tumor cells by contact with T lymphocytes loaded with Newcastle disease virus
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2009-04-01 / Int. J. Oncol. 2009 Apr;34(4):951-62Randomized clinical studies of anti-tumor vaccination: state of the art in 2008
/in Dendritic Cells, International Publications, IOZK Veröffentlichungen /von 2009-01-01 / Expert Rev Vaccines 2009 Jan;8(1):51-66Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2009-01-01 / Methods Mol. Biol. 2009;542:565-605Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study
/in Breast Cancer, Dendritic Cells, International Publications, IOZK Veröffentlichungen /von 2008-11-08 / Cancer Immunol. Immunother. 2009 Jun;58(6):887-900Activation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2008-10-01 / Int. J. Oncol. 2008 Oct;33(4):823-32Recombinant Newcastle disease virus expressing human interleukin-2 serves as a potential candidate for tumor therapy
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2008-06-05 / Virus Res. 2008 Sep;136(1-2):75-80Detection and functional analysis of tumor infiltrating T-lymphocytes (TIL) in liver metastases from colorectal cancer
/in Colorectal Cancer, International Publications, IOZK Veröffentlichungen /von 2008-06-03 / Ann. Surg. Oncol. 2008 Aug;15(8):2310-7Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial
/in Colorectal Cancer, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2008-05-17 / Cancer Immunol. Immunother. 2009 Jan;58(1):61-9An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2008-04-01 / Int. J. Oncol. 2008 Apr;32(4):777-89Second International Conference on Cancer Vaccines/Adjuvants/Delivery for the Next Decade (CVADD): Heidelberg, Germany, 10-12 October 2007
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2008-02-13 / Cancer Immunol. Immunother. 2008 Sep;57(9):1421-7Host mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application
/in International Publications, Newcastle Disease Virus /von 2007-11-01 / Int. J. Oncol. 2007 Nov;31(5):1009-19Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy
/in International Publications, Newcastle Disease Virus /von 2007-10-04 / Gene Ther. 2007 Dec;14(23):1639-49Role of tumor endothelium in CD4+ CD25+ regulatory T cell infiltration of human pancreatic carcinoma
/in International Publications, Pancreatic Cancer /von 2007-07-24 / J. Natl. Cancer Inst. 2007 Aug;99(15):1188-99Tumor infiltrating T lymphocytes in colorectal cancer: Tumor-selective activation and cytotoxic activity in situ
/in Colorectal Cancer, International Publications /von 2006-12-01 / Ann. Surg. 2006 Dec;244(6):986-92; discussion 992-3Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence
/in International Publications, Newcastle Disease Virus /von 2006-07-15 / Int. J. Cancer 2006 Jul;119(2):328-38A tumor vaccine containing anti-CD3 and anti-CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes
/in International Publications, Newcastle Disease Virus /von 2006-02-01 / Int. J. Cancer 2006 Feb;118(3):658-67Tumor-targeted gene transfer in vivo via recombinant Newcastle disease virus modified by a bispecific fusion protein
/in International Publications, Newcastle Disease Virus /von 2005-08-01 / Int. J. Oncol. 2005 Aug;27(2):377-84T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine
/in International Publications, Newcastle Disease Virus /von 2005-03-31 / Vaccine 2005 Mar;23(19):2439-53Selective gene transfer in vitro to tumor cells via recombinant Newcastle disease virus
/in International Publications, Newcastle Disease Virus /von 2005-03-01 / Cancer Gene Ther. 2005 Mar;12(3):295-303Selective gene transfer to tumor cells by recombinant Newcastle Disease Virus via a bispecific fusion protein
/in International Publications, Newcastle Disease Virus /von 2005-02-01 / Int. J. Oncol. 2005 Feb;26(2):431-9Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells
/in International Publications, Newcastle Disease Virus /von 2004-11-01 / Cancer Res. 2004 Nov;64(21):8057-61Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory
/in International Publications, Newcastle Disease Virus /von 2004-10-30 / Cancer Immunol. Immunother. 2005 Jun;54(6):587-98Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit
/in Dendritic Cells, Glioblastoma, International Publications, Newcastle Disease Virus /von 2004-09-27 / J. Clin. Oncol. 2004 Nov;22(21):4272-81High cell surface expression of Newcastle disease virus proteins via replicon vectors demonstrates syncytia forming activity of F and fusion promotion activity of HN molecules
/in International Publications, Newcastle Disease Virus /von 2004-08-01 / Int. J. Oncol. 2004 Aug;25(2):293-302Importance of serine 200 for functional activities of the hemagglutinin-neuraminidase protein of Newcastle Disease Virus
/in International Publications, Newcastle Disease Virus /von 2004-03-01 / Int. J. Oncol. 2004 Mar;24(3):623-34TNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle disease virus
/in International Publications, Newcastle Disease Virus /von 2003-02-15 / J. Immunol. 2003 Feb;170(4):1814-21Cognate interactions between memory T cells and tumor antigen-presenting dendritic cells from bone marrow of breast cancer patients: bidirectional cell stimulation, survival and antitumor activity in vivo
/in Breast Cancer, Dendritic Cells, International Publications /von 2003-01-01 / Int. J. Cancer 2003 Jan;103(1):73-83Influence of adjuvant hormone therapy and chemotherapy on the immune system analysed in the bone marrow of patients with breast cancer
/in Breast Cancer, International Publications /von 2003-01-01 / Clin. Cancer Res. 2003 Jan;9(1):174-80Editorial von Prof. Dr. Volker Schirrmacher zum Beitrag „Immuntherapeutische Strategien zur Behandlung solider Tumoren“
/in IOZK Veröffentlichungen /von IOZKHuman tumor cell infection by Newcastle Disease Virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis
/in Breast Cancer, Colorectal Cancer, Glioblastoma, International Publications, Newcastle Disease Virus /von 2002-07-01 / Int. J. Oncol. 2002 Jul;21(1):85-93Beitrag mit Prof. Dr. Schirrmacher über den Stellenwert der Dendritischen Zellen im Einsatz gegen Krebszellen
/in Externe Meldungen, IOZK In der Presse /von IOZKGeneration of dendritic cells from human bone marrow mononuclear cells: advantages for clinical application in comparison to peripheral blood monocyte derived cells
/in Dendritic Cells, International Publications /von 2002-02-01 / Int. J. Oncol. 2002 Feb;20(2):247-53Antitumor effects of Newcastle Disease Virus in vivo: local versus systemic effects
/in International Publications, Newcastle Disease Virus /von 2001-05-01 / Int. J. Oncol. 2001 May;18(5):945-52Tumor stimulator cell modification by infection with Newcastle Disease Virus: analysis of effects and mechanism in MLTC-CML cultures
/in International Publications, Newcastle Disease Virus /von 1999-02-01 / Int. J. Oncol. 1999 Feb;14(2):205-15Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus
/in International Publications, Newcastle Disease Virus /von 1999-01-01 / Gene Ther. 1999 Jan;6(1):63-73Introduction of adhesive and costimulatory immune functions into tumor cells by infection with Newcastle Disease Virus
/in International Publications, Newcastle Disease Virus /von 1998-12-01 / Int. J. Oncol. 1998 Dec;13(6):1105-15Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer
/in Breast Cancer, International Publications, Newcastle Disease Virus, Ovarian Cancer /von 1997-04-01 / J. Clin. Oncol. 1997 Apr;15(4):1354-66